Performance Graph The following graph compares the yearly change in the cumulative total stockholder return for our last five full fiscal years, based upon the market price of our common stock, with the cumulative total return on a Nasdaq Composite Index (U. S.  Companies) and a peer group, the Nasdaq Medical Equipment-SIC Code 3840-3849 Index, which is comprised of medical equipment companies, for that period.
The performance graph assumes the investment of $100 on March 31, 2006 in our Common Stock, the Nasdaq Composite Index (U. S.  Companies) and the peer group index, and the reinvestment of any and all dividends.
COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN* Among ABIOMED, Inc. , The NASDAQ Composite Index And The NASDAQ Medical Equipment SIC Code 3840-3849 Index
## Table 0 ##
This graph is not “soliciting material” under Regulation 14A or 14C of the rules promulgated under the Securities Exchange Act of 1934, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference in any of our filings under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
Transfer Agent American Stock Transfer & Trust Company, 59 Maiden Lane, New York, NY 10038, is our stock Transfer Agent.
PERFORMANCE GRAPH – The following graph compares the cumulative five-year total return provided shareholders on H&R Block, Inc. ’s common stock relative to the cumulative total returns of the S&P 500 index and the S&P Diversified Commercial & Professional Services index.
An investment of $100, with reinvestment of all dividends, is assumed to have been made in our common stock and in each of the indexes on April 30, 2005, and its relative performance is tracked through April 30, 2010.
## Table 1 ##
ITEM 6.
SELECTED FINANCIAL DATA We derived the selected consolidated financial data presented below as of and for each of the five years in the period ended April 30, 2010, from our audited consolidated financial statements.
The data set forth below should be read in conjunction with Item 7 and our consolidated financial statements in Item 8.
(1) Amounts represent dividends declared.
In fiscal year 2010, the dividend payable in July 2010 was declared in AprilITEM 7.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Our subsidiaries provide tax preparation, retail banking and various business advisory and consulting services.
We are the only major company offering a full range of software, online and in-office tax preparation solutions to individual tax clients.
Effective May 1, 2009, we realigned certain segments of our business to reflect a new management reporting structure.
The operations of HRB Bank, which was previously reported as the Consumer Financial Services segment, have now been reclassified, with activities that support our retail tax network included in the Tax Services segment, and the net interest margin and gains and losses relating to our portfolio of mortgage loans held for investment and related assets included in the corporate segment.
Presentation of prior period results reflects the new segment reporting structure.
employees.
These awards entitle the holder to shares or the right to purchase shares of common stock as the award vests, typically over a three-year period with one-third vesting each year.
Nonvested shares receive dividends during the vesting period and performance nonvested share units receive cumulative dividends at the end of the vesting period.
We measure the fair value of options on the grant date or modification date using the Black-Scholes option valuation model.
We measure the fair value of nonvested shares and performance nonvested share units based on the closing price of our common stock on the grant date.
Generally, we expense the grant-date fair value, net of estimated forfeitures, over the vesting period on a straight-line basis.
Awards granted to employees who are of retirement age or reach retirement age at least one year after the grant date, but prior to the end of the service period of the awards, are expensed over the shorter of the two periods.
Options are generally granted at a price equal to the fair market value of our common stock on the grant date and have a contractual term of ten years.
Our 1999 Stock Option Plan for Seasonal Employees, which provided for awards of nonqualified options to certain employees, was terminated effective December 31, 2009, except for outstanding awards thereunder.
These awards were granted to seasonal employees in our Tax Services segment and entitled the holder to the right to purchase shares of common stock as the award vests, typically over a two-year period.
We measure the fair value of options on the grant date using the Black-Scholes option valuation model.
We expense the grant-date fair value, net of estimated forfeitures, over the seasonal service period.
Options were granted at a price equal to the fair market value of our common stock on the grant date, are exercisable during September through November in each of the two years following the calendar year of the grant, and have a contractual term of 29 months.
Our 1989 Stock Option Plan for Outside Directors, which provided for awards of nonqualified options to outside directors, was terminated effective June 11, 2008, except for outstanding awards thereunder.
The plan was replaced by the 2008 Deferred Stock Unit Plan for Outside Directors.
The number of deferred stock units credited to an outside director’s account pursuant to an award is determined by dividing the dollar amount of the award by the average current market value per share of common stock for the ten consecutive trading dates ending on the date the deferred stock units are granted to the outside directors.
Each deferred stock unit granted is vested upon award and the settlement of shares occurs six months after separation of service from the Board of Directors.
The vested shares receive dividends prior to settlement, which are reinvested and settled in shares at the time of settlement.
Our 2000 Employee Stock Purchase Plan (ESPP) provides employees the option to purchase shares of our common stock through payroll deductions.
The purchase price of the stock is 90% of the lower of either the fair market value of our common stock on the first trading day within the Option Period or on the last trading day of the Option Period.
The Option Periods are six-month periods beginning on January 1 and July 1 each year.
We measure the fair value of options on the grant date utilizing the Black-Scholes option valuation model.
The fair value of the option includes the value of the 10% discount and the look-back feature.
We expense the grant-date fair value over the six-month vesting period.
A summary of options for the year ended April 30, 2010, is as follows:
## Table 2 ##
The total intrinsic value of options exercised during fiscal years 2010, 2009 and 2008 was $5.4 milllion, $33.0 million and $12.9 million, respectively.
As of April 30, 2010, we had $7.5 million of total unrecognized compensation cost related to these options.
The cost is expected to be recognized over a weighted-average period of two years.
We utilize the Black-Scholes option valuation model to value our options on the grant date.
We typically estimate the expected volatility using our historical stock price data, unless historical volatility is not representative of expected volatility.
We also use historical exercise and forfeiture behaviors to estimate the options expected term and our forfeiture rate.
The dividend yield is calculated based on the current dividend and the market price of our common stock on the grant date.
The risk-free interest rate is based on the U. S.  Treasury zero-coupon yield curve

<table><tr><td></td><td>3/31/2006</td><td>3/31/2007</td><td>3/31/2008</td><td>3/31/2009</td><td>3/31/2010</td><td>3/31/2011</td></tr><tr><td>ABIOMED, Inc</td><td>100</td><td>105.89</td><td>101.86</td><td>37.98</td><td>80.00</td><td>112.64</td></tr><tr><td>Nasdaq Composite Index</td><td>100</td><td>103.50</td><td>97.41</td><td>65.33</td><td>102.49</td><td>118.86</td></tr><tr><td>Nasdaq Medical Equipment SIC Code 3840-3849</td><td>100</td><td>88.78</td><td>84.26</td><td>46.12</td><td>83.47</td><td>91.35</td></tr></table>
<table><tr><td></td><td></td><td></td><td colspan="3">(in 000s, except per share amounts)</td></tr><tr><td>April 30,</td><td> 2010</td><td>2009</td><td>2008</td><td>2007</td><td>2006</td></tr><tr><td>Revenues</td><td>$3,874,332</td><td>$4,083,577</td><td>$4,086,630</td><td>$3,710,362</td><td>$3,286,798</td></tr><tr><td>Net income from continuing operations</td><td>488,946</td><td>513,055</td><td>445,947</td><td>369,460</td><td>310,811</td></tr><tr><td>Net income (loss)</td><td>479,242</td><td>485,673</td><td>-308,647</td><td>-433,653</td><td>490,408</td></tr><tr><td>Basic earnings (loss) per share:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Net income from continuing operations</td><td>$1.47</td><td>$1.53</td><td>$1.37</td><td>$1.14</td><td>$0.94</td></tr><tr><td>Net income (loss)</td><td>1.44</td><td>1.45</td><td>-0.95</td><td>-1.35</td><td>1.49</td></tr><tr><td>Diluted earnings (loss) per share:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Net income from continuing operations</td><td>$1.46</td><td>$1.53</td><td>$1.35</td><td>$1.13</td><td>$0.92</td></tr><tr><td>Net income (loss)</td><td>1.43</td><td>1.45</td><td>-0.95</td><td>-1.33</td><td>1.46</td></tr><tr><td>Total assets</td><td>$5,234,318</td><td>$5,359,722</td><td>$5,623,425</td><td>$7,544,050</td><td>$5,989,135</td></tr><tr><td>Long-term debt</td><td>1,035,144</td><td>1,032,122</td><td>1,031,784</td><td>537,134</td><td>417,262</td></tr><tr><td>Dividends per share<sup>-1</sup></td><td>$0.75</td><td>$0.59</td><td>$0.56</td><td>$0.53</td><td>$0.49</td></tr></table>
<table><tr><td></td><td>Shares</td><td>Weighted-Average  Exercise Price</td><td>Weighted-Average  Remaining  Contractual Term</td><td>Aggregate  Intrinsic Value</td></tr><tr><td>Outstanding, beginning of the year</td><td>16,401</td><td>$21.85</td><td></td><td></td></tr><tr><td>Granted</td><td>4,634</td><td>17.37</td><td></td><td></td></tr><tr><td>Exercised</td><td>-1,293</td><td>14.44</td><td></td><td></td></tr><tr><td>Forfeited or expired</td><td>-4,660</td><td>23.51</td><td></td><td></td></tr><tr><td>Outstanding, end of the year</td><td>15,082</td><td>$20.58</td><td> 4 years</td><td>$9,324</td></tr><tr><td>Exercisable, end of the year</td><td>8,973</td><td>$21.60</td><td> 3 years</td><td>$4,647</td></tr><tr><td>Exercisable and expected to vest</td><td>14,866</td><td>20.60</td><td> 4 years</td><td>9,205</td></tr></table>

Question: what is the roi of an investment in abiomed inc from march 2006 to march 2009?